The prognostic impact of lymphocyte subsets in newly diagnosed acute myeloid leukemia
Tumor-infiltrating lymphocytes, which form a part of the host immune system, affect the development and progression of cancer. This study investigated whether subsets of lymphocytes reflecting host-tumor immunologic interactions are related to the prognosis of patients with acute myeloid leukemia (A...
Saved in:
Published in | Blood research Vol. 53; no. 3; pp. 198 - 204 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Korea (South)
Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
01.09.2018
대한혈액학회 |
Subjects | |
Online Access | Get full text |
ISSN | 2287-979X 2288-0011 |
DOI | 10.5045/br.2018.53.3.198 |
Cover
Abstract | Tumor-infiltrating lymphocytes, which form a part of the host immune system, affect the development and progression of cancer. This study investigated whether subsets of lymphocytes reflecting host-tumor immunologic interactions are related to the prognosis of patients with acute myeloid leukemia (AML).
Lymphocyte subsets in the peripheral blood of 88 patients who were newly diagnosed with AML were analyzed by quantitative flow cytometry. The relationships of lymphocyte subsets with AML subtypes, genetic risk, and clinical courses were analyzed.
The percentages of T and NK cells differed between patients with acute promyelocytic leukemia (APL) and those with AML with myelodysplasia-related changes. In non-APL, a high proportion of NK cells (>16.6%) was associated with a higher rate of death before remission (
=0.0438), whereas a low proportion of NK cells (≤9.4%) was associated with higher rates of adverse genetic abnormalities (
=0.0244) and relapse (
=0.0567). A multivariate analysis showed that the lymphocyte subsets were not independent predictors of survival.
Lymphocyte subsets at diagnosis differ between patients with different specific subtypes of AML. A low proportion of NK cells is associated with adverse genetic abnormalities, whereas a high proportion is related to death before remission. However, the proportion of NK cells may not show independent correlations with survival. |
---|---|
AbstractList | Tumor-infiltrating lymphocytes, which form a part of the host immune system, affect the development and progression of cancer. This study investigated whether subsets of lymphocytes reflecting host-tumor immunologic interactions are related to the prognosis of patients with acute myeloid leukemia (AML).BACKGROUNDTumor-infiltrating lymphocytes, which form a part of the host immune system, affect the development and progression of cancer. This study investigated whether subsets of lymphocytes reflecting host-tumor immunologic interactions are related to the prognosis of patients with acute myeloid leukemia (AML).Lymphocyte subsets in the peripheral blood of 88 patients who were newly diagnosed with AML were analyzed by quantitative flow cytometry. The relationships of lymphocyte subsets with AML subtypes, genetic risk, and clinical courses were analyzed.METHODSLymphocyte subsets in the peripheral blood of 88 patients who were newly diagnosed with AML were analyzed by quantitative flow cytometry. The relationships of lymphocyte subsets with AML subtypes, genetic risk, and clinical courses were analyzed.The percentages of T and NK cells differed between patients with acute promyelocytic leukemia (APL) and those with AML with myelodysplasia-related changes. In non-APL, a high proportion of NK cells (>16.6%) was associated with a higher rate of death before remission (P=0.0438), whereas a low proportion of NK cells (≤9.4%) was associated with higher rates of adverse genetic abnormalities (P=0.0244) and relapse (P=0.0567). A multivariate analysis showed that the lymphocyte subsets were not independent predictors of survival.RESULTSThe percentages of T and NK cells differed between patients with acute promyelocytic leukemia (APL) and those with AML with myelodysplasia-related changes. In non-APL, a high proportion of NK cells (>16.6%) was associated with a higher rate of death before remission (P=0.0438), whereas a low proportion of NK cells (≤9.4%) was associated with higher rates of adverse genetic abnormalities (P=0.0244) and relapse (P=0.0567). A multivariate analysis showed that the lymphocyte subsets were not independent predictors of survival.Lymphocyte subsets at diagnosis differ between patients with different specific subtypes of AML. A low proportion of NK cells is associated with adverse genetic abnormalities, whereas a high proportion is related to death before remission. However, the proportion of NK cells may not show independent correlations with survival.CONCLUSIONLymphocyte subsets at diagnosis differ between patients with different specific subtypes of AML. A low proportion of NK cells is associated with adverse genetic abnormalities, whereas a high proportion is related to death before remission. However, the proportion of NK cells may not show independent correlations with survival. Background Tumor-infiltrating lymphocytes, which form a part of the host immune system, affect the development and progression of cancer. This study investigated whether subsets of lym-phocytes reflecting host-tumor immunologic interactions are related to the prognosis of patients with acute myeloid leukemia (AML). Methods Lymphocyte subsets in the peripheral blood of 88 patients who were newly diagnosed with AML were analyzed by quantitative flow cytometry. The relationships of lymphocyte subsets with AML subtypes, genetic risk, and clinical courses were analyzed. Results The percentages of T and NK cells differed between patients with acute promyelocytic leukemia (APL) and those with AML with myelodysplasia-related changes. In non-APL, a high proportion of NK cells (>16.6%) was associated with a higher rate of death before remission (P=0.0438), whereas a low proportion of NK cells (≤9.4%) was associated with higher rates of adverse genetic abnormalities (P=0.0244) and relapse (P=0.0567). A multivariate analysis showed that the lymphocyte subsets were not independent pre-dictors of survival. Conclusion Lymphocyte subsets at diagnosis differ between patients with different specific subtypes of AML. A low proportion of NK cells is associated with adverse genetic abnormalities, whereas a high proportion is related to death before remission. However, the proportion of NK cells may not show independent correlations with survival. KCI Citation Count: 1 Tumor-infiltrating lymphocytes, which form a part of the host immune system, affect the development and progression of cancer. This study investigated whether subsets of lymphocytes reflecting host-tumor immunologic interactions are related to the prognosis of patients with acute myeloid leukemia (AML). Lymphocyte subsets in the peripheral blood of 88 patients who were newly diagnosed with AML were analyzed by quantitative flow cytometry. The relationships of lymphocyte subsets with AML subtypes, genetic risk, and clinical courses were analyzed. The percentages of T and NK cells differed between patients with acute promyelocytic leukemia (APL) and those with AML with myelodysplasia-related changes. In non-APL, a high proportion of NK cells (>16.6%) was associated with a higher rate of death before remission ( =0.0438), whereas a low proportion of NK cells (≤9.4%) was associated with higher rates of adverse genetic abnormalities ( =0.0244) and relapse ( =0.0567). A multivariate analysis showed that the lymphocyte subsets were not independent predictors of survival. Lymphocyte subsets at diagnosis differ between patients with different specific subtypes of AML. A low proportion of NK cells is associated with adverse genetic abnormalities, whereas a high proportion is related to death before remission. However, the proportion of NK cells may not show independent correlations with survival. |
Author | Kim, Seonyoung Park, Yumi Lim, Jinsook Song, Ikchan Kwon, Kyechul Koo, Sunhoe Kim, Jimyung |
AuthorAffiliation | 2 Department of Hemato-Oncology, Chungnam National University Hospital, Daejeon, Korea 1 Department of Laboratory Medicine, Chungnam National University Hospital, Daejeon, Korea |
AuthorAffiliation_xml | – name: 1 Department of Laboratory Medicine, Chungnam National University Hospital, Daejeon, Korea – name: 2 Department of Hemato-Oncology, Chungnam National University Hospital, Daejeon, Korea |
Author_xml | – sequence: 1 givenname: Yumi surname: Park fullname: Park, Yumi organization: Department of Laboratory Medicine, Chungnam National University Hospital, Daejeon, Korea – sequence: 2 givenname: Jinsook surname: Lim fullname: Lim, Jinsook organization: Department of Laboratory Medicine, Chungnam National University Hospital, Daejeon, Korea – sequence: 3 givenname: Seonyoung surname: Kim fullname: Kim, Seonyoung organization: Department of Laboratory Medicine, Chungnam National University Hospital, Daejeon, Korea – sequence: 4 givenname: Ikchan surname: Song fullname: Song, Ikchan organization: Department of Hemato-Oncology, Chungnam National University Hospital, Daejeon, Korea – sequence: 5 givenname: Kyechul surname: Kwon fullname: Kwon, Kyechul organization: Department of Laboratory Medicine, Chungnam National University Hospital, Daejeon, Korea – sequence: 6 givenname: Sunhoe surname: Koo fullname: Koo, Sunhoe organization: Department of Laboratory Medicine, Chungnam National University Hospital, Daejeon, Korea – sequence: 7 givenname: Jimyung surname: Kim fullname: Kim, Jimyung organization: Department of Laboratory Medicine, Chungnam National University Hospital, Daejeon, Korea |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30310785$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002385320$$DAccess content in National Research Foundation of Korea (NRF) |
BookMark | eNp1kc1v1DAQxS1UREvpnRPyEQ4J_ojj-IJUVRQqVUJCW4mb5TiTrlknDnYCyn9f726LAAlfxpJ_773xzEt0MoYREHpNSSlIJd63sWSENqXgJS-pap6hM8aapiCE0pPDXRZKqm-n6CKl7ySfRkrFxAt0ygmnRDbiDN1ttoCnGO7HkGZnsRsmY2cceuzXYdoGu86A09ImmBN2Ix7hl19x58xeAB02dsnAsIIPrsMelh0MzrxCz3vjE1w81nN0d_1xc_W5uP3y6ebq8rawFSdzYRknrKlon1sF3nFWS2ANs31twdYt472wwliRf8QM5zy3rCrSg1XKykpafo7eHX3H2OuddToYd6j3Qe-ivvy6udFc1qypRWY_HNlpaQfoLIxzNF5P0Q0mrgfl3y-j22afn7qmMo-LZYO3jwYx_FggzXpwyYL3ZoSwJM0oVYqRulYZffNn1u-Qp7lnoD4CNoaUIvTautnMLuyjndeU6P2OdRv1fsdacM113nEWkn-ET97_lTwAFlip4g |
CitedBy_id | crossref_primary_10_1002_cyto_b_22197 crossref_primary_10_1007_s12308_023_00536_9 crossref_primary_10_1097_CEJ_0000000000000905 crossref_primary_10_1515_cclm_2021_0736 crossref_primary_10_3389_fcell_2021_800267 crossref_primary_10_5858_arpa_2023_0284_OA crossref_primary_10_15264_cpho_2019_26_1_1 |
Cites_doi | 10.4110/in.2014.14.6.289 10.1007/s00282-997-0301-3 10.1200/JCO.2003.04.036 10.3324/haematol.2013.087536 10.1038/sj.bjc.6601219 10.1038/cmi.2013.10 10.1007/BF01715050 10.4161/cbt.25938 10.1182/blood-2009-11-254441 10.1111/j.1365-2141.2008.07070.x 10.1038/sj.leu.2402835 10.1038/sj.leu.2403985 10.1182/blood-2016-03-643544 10.1038/sj.leu.2401452 10.3324/haematol.11702 10.1182/blood-2011-07-365817 10.3109/10428194.2015.1020060 10.1186/1479-5876-12-30 10.1111/ijlh.12594 10.1002/cyto.b.21349 10.1038/bjc.2011.189 10.1182/blood-2009-02-206946 10.1038/sj.leu.2400891 |
ContentType | Journal Article |
Copyright | 2018 Korean Society of Hematology 2018 Korean Society of Hematology |
Copyright_xml | – notice: 2018 Korean Society of Hematology 2018 Korean Society of Hematology |
DBID | AAYXX CITATION NPM 7X8 5PM ACYCR |
DOI | 10.5045/br.2018.53.3.198 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2288-0011 |
EndPage | 204 |
ExternalDocumentID | oai_kci_go_kr_ARTI_3762865 PMC6170312 30310785 10_5045_br_2018_53_3_198 |
Genre | Journal Article |
GroupedDBID | 0R~ 5-W 8JR 8XY 9ZL AAJSJ AAKKN AASML AAYXX ABEEZ ACACY ACULB ADBBV ADRAZ AFGXO ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL C24 C6C CITATION DIK EBLON EF. FRP HYE KQ8 M48 PGMZT RPM SOJ W2D M~E NPM OK1 RSV 7X8 5PM ACYCR |
ID | FETCH-LOGICAL-c430t-c2302841f287e3d3267e282cf6cec6b23f5c5ac50012a333078940fec99c747c3 |
IEDL.DBID | M48 |
ISSN | 2287-979X |
IngestDate | Sun Jan 21 03:11:41 EST 2024 Thu Aug 21 13:57:30 EDT 2025 Fri Jul 11 01:32:45 EDT 2025 Wed Feb 19 02:43:44 EST 2025 Thu Apr 24 23:08:35 EDT 2025 Tue Jul 01 01:58:59 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | NK cells Prognosis Acute myeloid leukemia Lymphocyte subset |
Language | English |
License | http://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c430t-c2302841f287e3d3267e282cf6cec6b23f5c5ac50012a333078940fec99c747c3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.5045/br.2018.53.3.198 |
PMID | 30310785 |
PQID | 2119920669 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_3762865 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6170312 proquest_miscellaneous_2119920669 pubmed_primary_30310785 crossref_citationtrail_10_5045_br_2018_53_3_198 crossref_primary_10_5045_br_2018_53_3_198 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2018-09-01 |
PublicationDateYYYYMMDD | 2018-09-01 |
PublicationDate_xml | – month: 09 year: 2018 text: 2018-09-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Korea (South) |
PublicationPlace_xml | – name: Korea (South) |
PublicationTitle | Blood research |
PublicationTitleAlternate | Blood Res |
PublicationYear | 2018 |
Publisher | Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 대한혈액학회 |
Publisher_xml | – name: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis – name: 대한혈액학회 |
References | Le Dieu (10.5045/br.2018.53.3.198_ref9) 2009; 114 Cheng (10.5045/br.2018.53.3.198_ref4) 2013; 10 Stringaris (10.5045/br.2018.53.3.198_ref10) 2014; 99 Ustun (10.5045/br.2018.53.3.198_ref23) 2011; 118 Woo (10.5045/br.2018.53.3.198_ref5) 2014; 12 (10.5045/br.2018.53.3.198_ref1) 1992; 41 Tzankov (10.5045/br.2018.53.3.198_ref6) 2008; 93 Ohnishi (10.5045/br.2018.53.3.198_ref14) 1998; 12 Guo (10.5045/br.2018.53.3.198_ref24) 2013; 14 Alcasid (10.5045/br.2018.53.3.198_ref8) 2017; 39 Bruserud (10.5045/br.2018.53.3.198_ref12) 1999; 13 Palmer (10.5045/br.2018.53.3.198_ref21) 2008; 141 Bar (10.5045/br.2018.53.3.198_ref16) 2015; 56 Mociková (10.5045/br.2018.53.3.198_ref7) 2010; 111 Siegler (10.5045/br.2018.53.3.198_ref13) 2005; 19 Arber (10.5045/br.2018.53.3.198_ref17) 2016; 127 Cheson (10.5045/br.2018.53.3.198_ref19) 2003; 21 Gooden (10.5045/br.2018.53.3.198_ref3) 2011; 105 Grimwade (10.5045/br.2018.53.3.198_ref18) 2010; 116 Aggarwal (10.5045/br.2018.53.3.198_ref22) 2016; 90 Vidriales (10.5045/br.2018.53.3.198_ref11) 1993; 67 Adami (10.5045/br.2018.53.3.198_ref2) 2003; 89 Parrado (10.5045/br.2018.53.3.198_ref15) 1997; 39 Panoskaltsis (10.5045/br.2018.53.3.198_ref25) 2003; 17 Choi (10.5045/br.2018.53.3.198_ref20) 2014; 14 10450745 - Leukemia. 1999 Aug;13(8):1175-87 14520450 - Br J Cancer. 2003 Oct 6;89(7):1221-7 18384436 - Br J Haematol. 2008 May;141(5):607-14 9436920 - Leukemia. 1998 Jan;12(1):52-8 24488563 - Haematologica. 2014 May;99(5):836-47 28133918 - Int J Lab Hematol. 2017 Apr;39(2):129-136 24475900 - J Transl Med. 2014 Jan 30;12:30 24030391 - Cancer Biol Ther. 2013 Oct 1;14(10):916-21 16224486 - Leukemia. 2005 Dec;19(12):2215-22 25726954 - Leuk Lymphoma. 2015;56(11):3109-15 18223287 - Haematologica. 2008 Feb;93(2):193-200 23604045 - Cell Mol Immunol. 2013 May;10(3):230-52 19710498 - Blood. 2009 Oct 29;114(18):3909-16 20359433 - Prague Med Rep. 2010;111(1):5-11 7694663 - Ann Hematol. 1993 Nov;67(5):217-22 1361652 - MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 20385793 - Blood. 2010 Jul 22;116(3):354-65 14673054 - J Clin Oncol. 2003 Dec 15;21(24):4642-9 26648320 - Cytometry B Clin Cytom. 2016 Jul;90(4):349-57 25550695 - Immune Netw. 2014 Dec;14(6):289-95 9497889 - Hematol Cell Ther. 1997 Dec;39(6):301-6 27069254 - Blood. 2016 May 19;127(20):2391-405 21629244 - Br J Cancer. 2011 Jun 28;105(1):93-103 12682629 - Leukemia. 2003 Apr;17(4):716-30 21881045 - Blood. 2011 Nov 10;118(19):5084-95 |
References_xml | – volume: 14 start-page: 289 year: 2014 ident: 10.5045/br.2018.53.3.198_ref20 publication-title: Immune Netw doi: 10.4110/in.2014.14.6.289 – volume: 39 start-page: 301 year: 1997 ident: 10.5045/br.2018.53.3.198_ref15 publication-title: Hematol Cell Ther doi: 10.1007/s00282-997-0301-3 – volume: 21 start-page: 4642 year: 2003 ident: 10.5045/br.2018.53.3.198_ref19 publication-title: J Clin Oncol doi: 10.1200/JCO.2003.04.036 – volume: 99 start-page: 836 year: 2014 ident: 10.5045/br.2018.53.3.198_ref10 publication-title: Haematologica doi: 10.3324/haematol.2013.087536 – volume: 41 start-page: 1 year: 1992 ident: 10.5045/br.2018.53.3.198_ref1 publication-title: MMWR Recomm Rep – volume: 89 start-page: 1221 year: 2003 ident: 10.5045/br.2018.53.3.198_ref2 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6601219 – volume: 10 start-page: 230 year: 2013 ident: 10.5045/br.2018.53.3.198_ref4 publication-title: Cell Mol Immunol doi: 10.1038/cmi.2013.10 – volume: 67 start-page: 217 year: 1993 ident: 10.5045/br.2018.53.3.198_ref11 publication-title: Ann Hematol doi: 10.1007/BF01715050 – volume: 14 start-page: 916 year: 2013 ident: 10.5045/br.2018.53.3.198_ref24 publication-title: Cancer Biol Ther doi: 10.4161/cbt.25938 – volume: 116 start-page: 354 year: 2010 ident: 10.5045/br.2018.53.3.198_ref18 publication-title: Blood doi: 10.1182/blood-2009-11-254441 – volume: 141 start-page: 607 year: 2008 ident: 10.5045/br.2018.53.3.198_ref21 publication-title: Br J Haematol doi: 10.1111/j.1365-2141.2008.07070.x – volume: 17 start-page: 716 year: 2003 ident: 10.5045/br.2018.53.3.198_ref25 publication-title: Leukemia doi: 10.1038/sj.leu.2402835 – volume: 19 start-page: 2215 year: 2005 ident: 10.5045/br.2018.53.3.198_ref13 publication-title: Leukemia doi: 10.1038/sj.leu.2403985 – volume: 111 start-page: 5 year: 2010 ident: 10.5045/br.2018.53.3.198_ref7 publication-title: Prague Med Rep – volume: 127 start-page: 2391 year: 2016 ident: 10.5045/br.2018.53.3.198_ref17 publication-title: Blood doi: 10.1182/blood-2016-03-643544 – volume: 13 start-page: 1175 year: 1999 ident: 10.5045/br.2018.53.3.198_ref12 publication-title: Leukemia doi: 10.1038/sj.leu.2401452 – volume: 93 start-page: 193 year: 2008 ident: 10.5045/br.2018.53.3.198_ref6 publication-title: Haematologica doi: 10.3324/haematol.11702 – volume: 118 start-page: 5084 year: 2011 ident: 10.5045/br.2018.53.3.198_ref23 publication-title: Blood doi: 10.1182/blood-2011-07-365817 – volume: 56 start-page: 3109 year: 2015 ident: 10.5045/br.2018.53.3.198_ref16 publication-title: Leuk Lymphoma doi: 10.3109/10428194.2015.1020060 – volume: 12 start-page: 30 year: 2014 ident: 10.5045/br.2018.53.3.198_ref5 publication-title: J Transl Med doi: 10.1186/1479-5876-12-30 – volume: 39 start-page: 129 year: 2017 ident: 10.5045/br.2018.53.3.198_ref8 publication-title: Int J Lab Hematol doi: 10.1111/ijlh.12594 – volume: 90 start-page: 349 year: 2016 ident: 10.5045/br.2018.53.3.198_ref22 publication-title: Cytometry B Clin Cytom doi: 10.1002/cyto.b.21349 – volume: 105 start-page: 93 year: 2011 ident: 10.5045/br.2018.53.3.198_ref3 publication-title: Br J Cancer doi: 10.1038/bjc.2011.189 – volume: 114 start-page: 3909 year: 2009 ident: 10.5045/br.2018.53.3.198_ref9 publication-title: Blood doi: 10.1182/blood-2009-02-206946 – volume: 12 start-page: 52 year: 1998 ident: 10.5045/br.2018.53.3.198_ref14 publication-title: Leukemia doi: 10.1038/sj.leu.2400891 – reference: 14520450 - Br J Cancer. 2003 Oct 6;89(7):1221-7 – reference: 18223287 - Haematologica. 2008 Feb;93(2):193-200 – reference: 21881045 - Blood. 2011 Nov 10;118(19):5084-95 – reference: 27069254 - Blood. 2016 May 19;127(20):2391-405 – reference: 24030391 - Cancer Biol Ther. 2013 Oct 1;14(10):916-21 – reference: 24475900 - J Transl Med. 2014 Jan 30;12:30 – reference: 25550695 - Immune Netw. 2014 Dec;14(6):289-95 – reference: 28133918 - Int J Lab Hematol. 2017 Apr;39(2):129-136 – reference: 7694663 - Ann Hematol. 1993 Nov;67(5):217-22 – reference: 10450745 - Leukemia. 1999 Aug;13(8):1175-87 – reference: 18384436 - Br J Haematol. 2008 May;141(5):607-14 – reference: 21629244 - Br J Cancer. 2011 Jun 28;105(1):93-103 – reference: 24488563 - Haematologica. 2014 May;99(5):836-47 – reference: 12682629 - Leukemia. 2003 Apr;17(4):716-30 – reference: 19710498 - Blood. 2009 Oct 29;114(18):3909-16 – reference: 9497889 - Hematol Cell Ther. 1997 Dec;39(6):301-6 – reference: 26648320 - Cytometry B Clin Cytom. 2016 Jul;90(4):349-57 – reference: 16224486 - Leukemia. 2005 Dec;19(12):2215-22 – reference: 23604045 - Cell Mol Immunol. 2013 May;10(3):230-52 – reference: 25726954 - Leuk Lymphoma. 2015;56(11):3109-15 – reference: 20385793 - Blood. 2010 Jul 22;116(3):354-65 – reference: 20359433 - Prague Med Rep. 2010;111(1):5-11 – reference: 1361652 - MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 – reference: 9436920 - Leukemia. 1998 Jan;12(1):52-8 – reference: 14673054 - J Clin Oncol. 2003 Dec 15;21(24):4642-9 |
SSID | ssj0000877925 |
Score | 2.140705 |
Snippet | Tumor-infiltrating lymphocytes, which form a part of the host immune system, affect the development and progression of cancer. This study investigated whether... Background Tumor-infiltrating lymphocytes, which form a part of the host immune system, affect the development and progression of cancer. This study... |
SourceID | nrf pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 198 |
SubjectTerms | Original 병리학 |
Title | The prognostic impact of lymphocyte subsets in newly diagnosed acute myeloid leukemia |
URI | https://www.ncbi.nlm.nih.gov/pubmed/30310785 https://www.proquest.com/docview/2119920669 https://pubmed.ncbi.nlm.nih.gov/PMC6170312 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002385320 |
Volume | 53 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | Blood Research, 2018, 53(3), , pp.198-204 |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lj9MwELbYRUJcVizP8lgZxIVDsmknj-aEENrVglROVOrNssc2RM0mbJpK5N8zk2QLRRXilEPsWJmxPd_nsT8L8Tb2vNRITFWD9UE8jW2gs8gEgAYpWoPWjjO6iy_p1TL-vEpWv49HjwbcHKR2fJ_UsinDnzfdexrwhF_DhBDJuWFdz-k8TCCEkEj0kbhLcSllKrYYwX4_L8-zLO9vYZ0RTQjyLF8NecuDH9mLU0dV4w9B0L93Uv4Rmi4fiJMRU8oPQyc4FXdc9VDcW4xZ80diSX1B8kasqmZVZjmcjJS1l2VHzqyxa53c0Azi2o0sKklIu-ykHTbhOSs1bqnAdefKurCydNu1uy70Y7G8vPj68SoYr1MIMIaoDZCcQsFo6unvHVjCbZkjwoU-RYepmYFPMNGYMALSAMBC9HHkHeY5EulAeCKOq7pyz4S0fmZsBJCaFOM0wrkz1rL2F_UHm_h4Is5vjadw1BrnKy9KRZyDza1Mo9jcKgEFisw9Ee92NX4MOhv_KPuG_KHWWCgWx-bnt1qtG0UU4JOiGZNP207E61t3KRoxnAbRlau3G8Wadjmr2OcT8XRw365JYKXUbE61sz3H7gpwg_tvquJ7r8rNyvYwnT3_j3ZfiPv8Q8NWtZfiuG227hVhm9ac9V32rF90-gU1n_fU |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+prognostic+impact+of+lymphocyte+subsets+in+newly+diagnosed+acute+myeloid+leukemia&rft.jtitle=Blood+research&rft.au=Park%2C+Yumi&rft.au=Lim%2C+Jinsook&rft.au=Kim%2C+Seonyoung&rft.au=Song%2C+Ikchan&rft.date=2018-09-01&rft.issn=2287-979X&rft.volume=53&rft.issue=3&rft.spage=198&rft_id=info:doi/10.5045%2Fbr.2018.53.3.198&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2287-979X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2287-979X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2287-979X&client=summon |